Where we at?, page-393

Gans, I reckon Huts is well within his own rights to be positive. It looks like you both have read the same SW document and depending on which window you look through, you could form a different view on the 2mg dose and then the pathway to blockbuster (or delisting). Enormous hurdle to overcome, yes, but after that… the original thesis that got us all excited is alive and well. Not for the faint hearted and given our cash position is unlikely to run out while the FDA comb through our data, our shot clock has a few more seconds on it than I had concluded a few weeks ago.